drugset / Trial / NCT04958772

Biosimilarity Study of Subcutaneous Filgrastim in Healthy Volunteers

NCT04958772

Phase 1 Not yet recruiting 100 enrolled Megalabs
RandomizedCrossoverOpen-labelTreatment

Summary

This study will compare the pharmacokinetics and pharmacodynamics, after single subcutaneous application, in healthy men, between filgrastim formulation, produced by Megalabs (test product) and Granulokine® (reference product) Amgen.

Timeline

Start
2024-11-01
Primary completion
2025-04-30
Completion
2025-05-31

Drugs

EvaluationDrugModalityDoseRoute
Subject filgrastim Protein / enzyme biologic 5 ug/kg Subcutaneous

Indications

No indication recorded.